Marinomed Biotech AG (WBO:MARI) FCF Margin %: -175.44% (As of Dec. 2025)

What is Marinomed Biotech AG FCF Margin %?

Marinomed Biotech AG WBO:MARI +2.78% 42 FCF Margin % is -175.44% as of Dec. 2025. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.48 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, Marinomed Biotech AG ranks better than 65.9% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Marinomed Biotech AG's Free Cash Flow for the six months ended in Dec. 2025 was €-0.90 Mil. Marinomed Biotech AG's Revenue for the six months ended in Dec. 2025 was €0.51 Mil. Therefore, Marinomed Biotech AG's FCF Margin % for the quarter that ended in Dec. 2025 was -175.44%.

As of today, Marinomed Biotech AG's current FCF Yield % is -5.95%.

The historical rank and industry rank for Marinomed Biotech AG's FCF Margin % or its related term are showing as below:

WBO:MARI' s FCF Margin % Range Over the Past 10 Years
Min: -162.44 Med: -50.16 Max: -14.3
Current: -14.3

During the past 11 years, the highest FCF Margin % of Marinomed Biotech AG was -14.30%. The lowest was -162.44%. And the median was -50.16%.

WBO:MARI's FCF Margin % is ranked better than
65.9% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs WBO:MARI: -14.30

Marinomed Biotech AG FCF Margin % Related Terms

Marinomed Biotech AG FCF Margin % Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG FCF Margin % Chart

Marinomed Biotech AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-49.75

-48.16

-42.27

-50.56

-14.30

Marinomed Biotech AG Semi-Annual Data
	Dec15	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
FCF Margin %	Get a 7-Day Free Trial														-37.35	-74.41	-25.77	-2.79	-175.44

WBO:MARI vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Marinomed Biotech AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marinomed Biotech AG FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's FCF Margin % falls into.

Save Embed

42GF Score

Marinomed Biotech AG WBO:MARI

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Marinomed Biotech AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Marinomed Biotech AG's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-1.1	/	7.691
	=	-14.30 %

Marinomed Biotech AG's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-0.9	/	0.513
	=	-175.44 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -175.44% mean?

Marinomed Biotech AG (WBO:MARI) has a FCF Margin % of -175.44% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #327 out of 959 companies in the Biotechnology industry, placing it in the top 34.1%.

Is Marinomed Biotech AG's FCF Margin % too high?

Marinomed Biotech AG's current FCF Margin % is -175.44%. Based on the distribution chart, Marinomed Biotech AG ranks #327 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Marinomed Biotech AG's FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #327 out of 959 companies for FCF Margin %. This puts Marinomed Biotech AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current FCF Margin % is -175.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Marinomed Biotech AG stock overvalued right now?

Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.48, compared to a current price of €9.25 — trading 49.9% below its estimated fair value. The current FCF Margin % is -175.44%. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current FCF Margin % is -175.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €9.25 is trading 49.9% below its estimated GF Value™ of €18.48. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

FCF Margin %: -175.44%
GF Value™: €18.48 vs. price of €9.25 (49.9% below fair value)
GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marinomed Biotech AG Business Description

Industry Healthcare Biotechnology

Comparable Companies VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM ROIV INCY MRNA HKSE:01801 HKSE:02269 OCSE:GMAB JAZZ

Other Exchanges 93Z:Germany

Address Hovengasse 25, Korneuburg, AUT, 2100

Website https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.

42GF Score

Get the complete analysis for WBO:MARI

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.25

Price

€18.48

GF Value

View WBO:MARI Analysis

See FCF Margin % data for all stocks →